EUVIMED · CrossrefZeitschrift
Transplantation and Cellular Therapy
ISSN 2666-6367 · Elsevier BV
Neueste Artikel
Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-Adapted Prevention Strategy
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival
Trends and Disparities in Chimeric Antigen Receptor T-Cell Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017 to 2022)
Clinical Trials in Graft-Versus-Host Disease: Changes in Study Characteristics, Investigated Drugs, and Endpoints Over Time
The Effect of Belumosudil on the Therapeutic Drug Levels of Tacrolimus and Sirolimus in Allogeneic Hematopoietic Transplantation
Association of a Digital Clinical Decision Support Platform With Early Outcomes After Pediatric Allogeneic Hematopoietic Cell Transplantation: A Three-Era Guideline Implementation Cohort Study
Absence of Pretransplant Peripheral Blasts is Favorable Factor in Allogeneic Stem Cell Transplantation for Advanced Acute Lymphoblastic Leukemia
Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes
Combination of Ruxolitinib and Extracorporeal Photopheresis as Third or Subsequent Line of Therapy for Steroid-dependent/Resistant Acute and Chronic GVHD
Comparison of Carmustine-, Lomustine-, and Nitrosourea-Free Conditioning Regimens for Autologous HCT (Auto-HCT) in Lymphoma: Results From the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR)
Haploidentical Versus HLA-matched Unrelated Donors for Hematopoietic Cell Transplantation in Acute Leukemia: A Multicenter Observational Study in a Developing Country Facilitated by Collaboration Between the CIBMTR and the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO)
Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma
A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia
Real-World Safety, Efficacy, and Immune Recovery Following Out-of-Specification Ciltacabtagene Autoleucel in Multiple Myeloma
Predictors of Rehabilitation Utilization After CAR T-Cell Therapy
Overcoming Donor-Specific Anti-Human Leukocyte Antigen Antibodies With Desensitization in Adult Ex-Vivo T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation: A Real-World Analysis
Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas
International Survey and Next-Generation Sequencing-Based Indel Chimerism Detection of Human Leukocyte Antigens Loss in Relapsed Haploidentical and Mismatched Unrelated Donor Transplant Recipients
Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies: A Prospective Trial
Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Real-World Use of Maribavir for Refractory CMV Infection and Intolerance to Conventional Anti-CMV Agents After Allogeneic Hematopoietic Cell Transplantation
Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation
Comment on “Tooth Loss and Oral Health-Related Quality of Life in a Subcohort within the Chronic Graft-versus-Host Disease Consortium”
Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy
Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation
Discontinuing Ciprofloxacin Prophylaxis in Allogeneic Stem Cell Transplantation Does Not Result in Inferior Outcomes
EUVIMED